Loading...
XBRUOXUR
Market cap696kUSD
Dec 20, Last price  
0.27EUR
1D
3.46%
1Q
-48.47%
Jan 2017
-100.00%
IPO
-100.00%
Name

Oxurion NV

Chart & Performance

D1W1MN
XBRU:OXUR chart
P/E
—
P/S
2.54
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
112.36%
Rev. gr., 5y
-45.20%
Revenues
263k
-55.80%
3,243,0001,252,00030,421,0004,213,0006,175,0002,476,00075,083,000112,781,00013,776,00011,198,0007,104,0005,810,0005,320,0003,946,0002,077,9991,128,000595,000263,000
Net income
-19m
L-40.13%
-10,134,000-15,967,00012,095,000-14,070,000-13,942,000-21,637,00030,415,00026,401,000-51,115,000-37,884,000-60,314,00022,788,000-38,474,000-51,827,000-28,012,000-29,158,000-31,685,000-18,969,000
CFO
-10m
L-51.21%
-8,418,000-14,797,00011,957,000-12,098,000-16,842,000-19,564,00027,789,00025,710,000-46,579,000-27,793,000-20,309,00026,295,000-31,116,000-31,100,000-27,097,000-27,155,000-20,016,000-9,765,000

Profile

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
URL
https://www.oxurion.com
IPO date
Jul 07, 2006
Employees
27
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
263
-55.80%
595
-47.25%
1,128
-45.72%
Cost of revenue
12,826
23,422
29,909
Unusual Expense (Income)
NOPBT
(12,563)
(22,827)
(28,781)
NOPBT Margin
Operating Taxes
3
7
3
Tax Rate
NOPAT
(12,566)
(22,834)
(28,784)
Net income
(18,969)
-40.13%
(31,685)
8.67%
(29,158)
4.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,405
1,350
BB yield
-0.06%
0.00%
Debt
Debt current
12,217
3,948
3,622
Long-term debt
445
4,068
8,477
Deferred revenue
Other long-term liabilities
12
992
638
Net debt
10,988
4,425
2,112
Cash flow
Cash from operating activities
(9,765)
(20,016)
(27,155)
CAPEX
(1,000)
(59)
(32)
Cash from investing activities
72
106
484
Cash from financing activities
7,822
13,643
11,878
FCF
(8,394)
(22,229)
(27,857)
Balance
Cash
1,674
3,591
9,987
Long term investments
Excess cash
1,661
3,561
9,931
Stockholders' equity
(13,436)
(4,833)
(1,342)
Invested Capital
12,596
8,425
12,927
ROIC
ROCE
1,495.60%
EV
Common stock shares outstanding
1,652,094
85,020
38,411
Price
190.00
-98.95%
18,160.00
-28.92%
Market cap
16,153,768
-97.68%
697,535,261
-28.70%
EV
16,158,193
697,537,343
EBITDA
(12,167)
(22,474)
(28,104)
EV/EBITDA
Interest
1,969
1,370
739
Interest/NOPBT